BioMarin Pharmaceutical, Inc.

Organization Address
770 Lindaro
San Rafael, CA 94901-3991

Organization Phone
(415) 506-6700



Organization Description

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio is comprised of two approved products and multiple investigational product candidates. Orapred® (prednisolone sodium phosphate oral solution) is approved in the United States for exacerbations of asthma and other inflammatory conditions, and Aldurazyme® (laronidase) is approved in the United States, European Union, Canada, Australia, and additional countries for mucopolysaccharidosis I (MPS I). Investigational product candidates for genetic diseases include rhASB (galsulfase) for mucopolysaccharidosis VI (MPS VI), Phenoptin™ (sapropterin hydrochloride) for phenylketonuria (PKU), and Phenylase™ (phenylalanine ammonia lyase), a preclinical candidate for severe PKU. The company is also evaluating enzyme-based therapies for serious medical conditions including Vibrilase™ (vibriolysin), a topical enzyme therapy that is in development for the debridement of serious burns. For additional information about BioMarin and its product pipeline, please visit

Clinical Development Stage